Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1983 Jun;17(6):411-7.
doi: 10.1177/106002808301700601.

Comparative effects and analgesic efficacy of the agonist-antagonist opioids

E M Zola, D C McLeod
Comparative Study

Comparative effects and analgesic efficacy of the agonist-antagonist opioids

E M Zola et al. Drug Intell Clin Pharm. 1983 Jun.

Abstract

Pentazocine, butorphanol, nalbuphine, and buprenorphine are mixed agonist-antagonist opioids that are effective analgesics, with less abuse potential than the agonists morphine, propoxyphene, and codeine. The dual properties of the agonist-antagonists are largely explained by their varying actions at the postulated three types (mu, chi, and sigma) of opioid receptors. The agonist-antagonists are classified as either morphine-like or nalorphine-like, based on their acute effects and withdrawal symptoms after chronic dosing. Buprenorphine is morphine-like, while the other drugs are nalorphine-like. These agents vary in the duration of analgesia, with pentazocine having a mean action of three hours and buprenorphine greater than six hours. The hemodynamic effects of nalbuphine and buprenorphine generally resemble those of morphine, while pentazocine and butorphanol increase cardiac workload, blood pressure, and pulmonary artery pressure. The agonist-antagonists have ceilings for respiratory depression, whereas the agonists produce dose-dependent depression. Agonist-antagonists generally produce less increase in biliary ductal pressure than does morphine. The major clinical limitations are that agonist-dependent patients may experience unpleasant subjective effects, when treated with the agonist-antagonists, and the nalorphine-like agents can produce psychotomimetic effects. More clinical experience is needed to rank the abuse potential within this group of opioids. The newer agents are being studied for oral use in acute and chronic pain.

PubMed Disclaimer

Similar articles

  • Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ, Hanks GW. Hoskin PJ, et al. Drugs. 1991 Mar;41(3):326-44. doi: 10.2165/00003495-199141030-00002. Drugs. 1991. PMID: 1711441 Review.
  • Nalbuphine.
    Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG. Schmidt WK, et al. Drug Alcohol Depend. 1985 Feb;14(3-4):339-62. doi: 10.1016/0376-8716(85)90066-3. Drug Alcohol Depend. 1985. PMID: 2986929 Review.
  • Opioids, Opioid Antagonists.
    [No authors listed] [No authors listed] 2020 Nov 24. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Nov 24. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643200 Free Books & Documents. Review.
  • Clinical observations of agonist-antagonist analgesic dependence.
    Peachey JE. Peachey JE. Drug Alcohol Depend. 1987 Dec;20(4):347-65. doi: 10.1016/0376-8716(87)90008-1. Drug Alcohol Depend. 1987. PMID: 2894289 Review.
  • Which potent opioid? Important criteria for selection.
    Bovill JG. Bovill JG. Drugs. 1987 May;33(5):520-30. doi: 10.2165/00003495-198733050-00006. Drugs. 1987. PMID: 2954811
See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources